TOTS3:BMFBOVESPATOTVS S.A. Analysis
Data as of 2026-03-12 - not real-time
R$37.57
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
TOTVS (TOTS3) is trading at R$37.57, just below its 20‑day simple moving average of R$37.81 but well under the 50‑day (R$41.07) and 200‑day (R$42.69) averages, indicating short‑term pressure in a bearish market context. The RSI sits at 42.9, suggesting neither overbought nor oversold conditions, while the MACD histogram is positive and the MACD line sits above its signal, delivering a bullish technical signal that tempers the downtrend. Volume has been on a decreasing trend, and 30‑day volatility is elevated at 48%, reflecting a choppy trading environment. The stock’s beta of 0.22 points to low systematic risk despite the high price swings.
Fundamentally, TOTVS delivers strong profitability with a 70% gross margin, 21.5% operating margin and a 15% year‑over‑year revenue growth, while its ROE of 16% and free cash flow generation support a sustainable dividend yield of 1.64% and a payout ratio of 43%. The forward P/E of 16.6 is well below the sector average of 34.6, and the current P/E of 26.6 also signals relative value, although a discounted cash‑flow model pins fair value near R$10, implying the market may be pricing in growth expectations. The balance sheet is moderate, with a debt‑to‑equity of 33.7% and ample cash reserves. Taken together, the blend of solid earnings, attractive dividend and upside potential makes the stock a candidate for medium‑ to long‑term accumulation, while short‑term caution is warranted.
Fundamentally, TOTVS delivers strong profitability with a 70% gross margin, 21.5% operating margin and a 15% year‑over‑year revenue growth, while its ROE of 16% and free cash flow generation support a sustainable dividend yield of 1.64% and a payout ratio of 43%. The forward P/E of 16.6 is well below the sector average of 34.6, and the current P/E of 26.6 also signals relative value, although a discounted cash‑flow model pins fair value near R$10, implying the market may be pricing in growth expectations. The balance sheet is moderate, with a debt‑to‑equity of 33.7% and ample cash reserves. Taken together, the blend of solid earnings, attractive dividend and upside potential makes the stock a candidate for medium‑ to long‑term accumulation, while short‑term caution is warranted.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- price below 20‑day SMA
- decreasing volume trend
- MACD bullish divergence amid bearish price action
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- 15% revenue growth YoY
- forward P/E of 16.6 versus industry average of 34.6
- sustainable dividend with 43% payout ratio
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- high gross margin and recurring software revenue model
- strong free cash flow generation
- moderate leverage and solid cash cushion
Key Metrics & Analysis
Financial Health
Revenue Growth15.10%
Profit Margin15.45%
P/E Ratio26.6
ROE16.14%
ROA7.58%
Debt/Equity33.73
P/B Ratio4.3
Op. Cash FlowR$1.2B
Free Cash FlowR$228.1M
Industry P/E34.6
Technical Analysis
TrendBearish
RSI42.9
SupportR$0.00
ResistanceR$40.00
MA 20R$37.81
MA 50R$41.07
MA 200R$42.69
MACDBullish
VolumeDecreasing
Fear & Greed Index78.16
Valuation
Fair ValueR$10.00
Target PriceR$51.52
Upside/Downside37.14%
GradeFair
TypeBlend
Dividend Yield1.64%
Risk Assessment
Beta0.22
Volatility48.38%
Sector RiskHigh
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.